2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC – IASLC
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC – IASLC RAS(ON) Inhibition: On the Path to Overcoming Therapeutic Resistance and Targeting More Variants in KRAS-Mutated NSCLC. Join this engaging CME symposium exploring the evolving treatment landscape of KRAS-mutated NSCLC....
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC - IASLC
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC - IASLC / Alex Spira, cancer, International Association for the Study of Lung Cancer, Kathryn Alex Spira and Kathryn C. Arbour 2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC –...
Lung adenocarcinoma with KRAS-Q61H: clinicopathologic features, diagnostics, and the evolving treatment landscape
KRAS is one of the most frequently mutated oncogenes in lung adenocarcinoma (LUAD), with the KRAS-Q61H mutation representing a rare but biologically distinct Introduction Lung adenocarcinoma is the most common histologic subtype of non-small cell lung cancer (NSCLC) and is...
Selinexor and Docetaxel Indicate Promise in KRAS-Mutant NSCLC
In this interview, Mitchell von Itzstein, MD, discusses the challenges of treating KRAS-mutant non-small cell lung cancer (NSCLC), the potential of selinexor in combination with docetaxel, and the need for further research to refine treatment strategies for this patient population....
Stage Ⅳb Pulmonary Sarcomatoid Carcinoma with EGFR L861Q KRAS Co-mutation and High PD-L1 Expression Neoadjuvant Immunochemotherapy Combined with Surgery Achieves Near MPR
You are reading this latest preprint version Background Pulmonary sarcomatoid carcinoma (PSC) is a rare, highly aggressive non-small cell lung cancer (NSCLC) subtype (0.1%–4% of lung malignancies)[3]. Clinically, it mainly affects smokers, with half diagnosed at advanced stages; pathologically, it...